An article in BioWorld Today, March 25, 2011, about Tarsa Therapeutics Inc. should have said that Tarsa reported positive top-line data from its Phase III postmenopausal osteoporosis trial, and Tarsa expects to file a marketing authorization application in Europe in early 2012. Unigene Laboratories Inc. licensed the oral calcitonin program to Tarsa in 2009 and is not responsible for further regulatory, clinical or commercialization efforts.

Editor's note: The correction has been made in BioWorld Online.